Pharmacodynamics of the S1P receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE.

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by autoreactive T and B lymphocytes. Sphingosine-1- phosphate (S1P) is involved in lymphocyte egress from peripheral lymphoid organs into the circulation. In phase 2a clinical trial, the potent, selective S1P receptor modulator cenerimod reduced circulating antibody-secreting cells and interferon (IFN)-associated biomarkers.